Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBA going "toe-to-toe" with athlete's foot

This article was originally published in The Tan Sheet

Executive Summary

Lamisil AT athlete's foot treatment becomes "an official sponsor of the NBA" and will be promoted by NBA All-Star Grant Hill of the Detroit Pistons under a multi-year agreement, the National Basketball Association and Novartis Consumer Health announce April 3. TV, print and Web-based advertising will debut in June, with "strength, speed and endurance" continuing as the tagline. The Lamisil AT campaign is being handled by Grey Advertising (New York). Lamisil AT Cream debuted last year; the line soon will be extended to include a spray pump and solution dropper (1"The Tan Sheet" March 27, p. 10)

You may also be interested in...



Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1

Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS091040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel